Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ICONIC: Carbon Ion Radiotherapy and Pembrolizumab in Stable Solid Cancers
NCT05229614Phase 2Recruiting
- Sponsor
- Fondazione Centro Nazionale di Adroterapia Oncologica
- Start
- Jul 2022
- Primary completion
- Aug 2025
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial, sponsored by Fondazione Centro Nazionale di Adroterapia Oncologica. Primary endpoint: Objective Response Rate at 8 weeks. Started Jul 2022; status: recruiting.
Beyond the preview
Go deeper on NCT05229614.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05229614.